Daito PharmaceuticalDaito Pharmaceutical Co., Ltd.4577東証プライム医薬品FY ending May 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥7 is left as operating profit. Revenue changed +0.0% from the prior year, operating profit +38.9%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 10.7% | 0.67× | 7.2% | 1.40× | 10.1% |
| 2023 | 8.0% | 0.67× | 5.3% | 1.42× | 7.5% |
| 2024 | 7.0% | 0.63× | 4.4% | 1.49× | 6.6% |
| 2025 | 3.8% | 0.65× | 2.5% | 1.54× | 3.8% |
| 2026 | 6.2% | 0.67× | 4.2% | 1.49× | 6.2% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending May 2022 | FY ending May 2023 | FY ending May 2024 | FY ending May 2025 | FY ending May 2026 |
|---|---|---|---|---|---|
| Revenue | 43,464 | 45,101 | 46,895 | 50,643 | 50,650 |
| Cost of revenue | 32,005 | 34,770 | 37,056 | 42,005 | 40,753 |
| Gross profit | 11,458 | 10,331 | 9,839 | 8,637 | 9,897 |
| SG&A | 4,905 | 5,123 | 5,945 | 6,017 | 6,260 |
| Operating income | 6,553 | 5,207 | 3,894 | 2,619 | 3,637 |
| Pretax income | 6,720 | 5,076 | 4,218 | 2,958 | 4,065 |
| Income tax | 2,092 | 1,549 | 1,040 | 1,192 | 928 |
| Net income attributable to owners | 4,668 | 3,600 | 3,295 | 1,908 | 3,161 |
| Operating margin | 15.1% | 11.5% | 8.3% | 5.2% | 7.2% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending May 2022 | FY ending May 2023 | FY ending May 2024 | FY ending May 2025 | FY ending May 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥4.38B | ¥3.61B | ¥2.73B | ¥2.21B | ¥954M |
| Total assets | ¥64.9B | ¥70.6B | ¥77.7B | ¥78B | ¥73.3B |
| Net assets | ¥47.7B | ¥51B | ¥52.3B | ¥52.1B | ¥52.9B |
| Share capital | ¥7.03B | ¥7.19B | ¥7.19B | ¥7.19B | ¥7.19B |
| Property, plant and equipment | ¥23.1B | ¥25.8B | ¥32B | ¥31.8B | ¥30.7B |
| Intangible assets excluding goodwill | ¥386M | ¥377M | ¥490M | ¥531M | ¥1.71B |
| Investment securities | ¥2.75B | ¥2.96B | ¥3.19B | ¥2.09B | ¥2.19B |
| Current assets | ¥37.9B | ¥40.7B | ¥41.5B | ¥41.7B | ¥36.6B |
| Current liabilities | ¥14.1B | ¥15.4B | ¥18.5B | ¥17B | ¥14B |
| Trade payables | ¥4.49B | ¥4.43B | ¥5.26B | ¥4.68B | ¥5.23B |
| Long-term borrowings | ¥2.25B | ¥3.37B | ¥4.67B | ¥6.57B | ¥3.75B |
| Total liabilities | ¥17.3B | ¥19.6B | ¥25.4B | ¥25.9B | ¥20.4B |
| Non-controlling interests | ¥367M | ¥299M | ¥196M | ¥64M | ¥46M |
| Equity attributable to owners of parent | ¥46.3B | ¥49.1B | ¥50.4B | ¥50.7B | ¥51.1B |
| Retained earnings | ¥32.3B | ¥35B | ¥37.1B | ¥37.2B | ¥37B |
| Treasury stock | -¥13M | -¥124M | -¥990M | -¥749M | -¥128M |
EDINET (FSA Japan)
有価証券報告書－第84期(2025/06/01－2026/05/31)
EDINET (FSA Japan)
有価証券報告書－第83期(2024/06/01－2025/05/31)
EDINET (FSA Japan)
有価証券報告書－第82期(2023/06/01－2024/05/31)
EDINET (FSA Japan)
有価証券報告書－第81期(2022/06/01－2023/05/31)
EDINET (FSA Japan)
有価証券報告書－第80期(令和3年6月1日－令和4年5月31日)
EDINET (FSA Japan)
有価証券報告書－第79期(令和2年6月1日－令和3年5月31日)
Extracted from XBRL: 52 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.